Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143800
Corporate User License Price USD 6000
Corporate User License Price INR 431400
Site License Price USD 4000
Site License Price INR 287600
Request a Quote

Report Title

B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2016



Executive Summary

B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2016

Summary

Global Markets Direct's, B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2016', provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia

The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects

The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

B-Cell Chronic Lymphocytic Leukemia Overview 10

Therapeutics Development 11

Pipeline Products for B-Cell Chronic Lymphocytic Leukemia-Overview 11

Pipeline Products for B-Cell Chronic Lymphocytic Leukemia-Comparative Analysis 12

B-Cell Chronic Lymphocytic Leukemia-Therapeutics under Development by Companies 13

B-Cell Chronic Lymphocytic Leukemia-Therapeutics under Investigation by Universities/Institutes 15

B-Cell Chronic Lymphocytic Leukemia-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

B-Cell Chronic Lymphocytic Leukemia-Products under Development by Companies 19

B-Cell Chronic Lymphocytic Leukemia-Products under Investigation by Universities/Institutes 21

B-Cell Chronic Lymphocytic Leukemia-Companies Involved in Therapeutics Development 22

AB Science SA 22

Aduro BioTech, Inc. 23

Amgen Inc. 24

Celgene Corporation 25

Cell Source, Inc. 26

Dynavax Technologies Corporation 27

Eisai Co., Ltd. 28

Elsalys Biotech SAS 29

F. Hoffmann-La Roche Ltd. 30

iDD biotech SAS 31

Immunomedics, Inc. 32

Johnson & Johnson 33

Juno Therapeutics Inc. 34

Lymphocyte Activation Technologies, S.A. 35

MedImmune, LLC 36

MEI Pharma, Inc. 37

Millennium Pharmaceuticals Inc 38

Molecular Templates Inc. 39

Noxxon Pharma AG 40

Ono Pharmaceutical Co., Ltd. 41

Regeneron Pharmaceuticals Inc 42

Sunesis Pharmaceuticals, Inc. 43

TheraMAB LLC 44

Unum Therapeutics, Inc. 45

B-Cell Chronic Lymphocytic Leukemia-Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Combination Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

202-b-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

AB-8779-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

alemtuzumab biosimilar-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

alisertib-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

AMG-319-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

BB-001-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

BION-1301-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Cellular Immunotherapy for Chronic Lymphocytic Leukaemia-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Cellular Immunotherapy for Hematological Malignancies-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Cellular Immunotherapy to Target CD19 for B-Cell Malignancies-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Cellular Immunotherapy to Target CD19 for Oncology-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Cellular Immunotherapy to Target CD19 for Oncology-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Cellular Immunotherapy to Target CD19 for Oncology-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

durvalumab-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

E-7449-Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

IDD-001-Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

IDD-002-Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

JNJ-64052781-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

lenalidomide-Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

MAT-303-Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

ME-401-Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

mRNA ACTR + rituximab-Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

MT-3724-Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

olaptesed pegol-Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

ONO-4059-Drug Profile 123

Product Description 123

Mechanism Of Action 123

R&D Progress 123

REGN-1979-Drug Profile 125

Product Description 125

Mechanism Of Action 125

R&D Progress 125

SD-101-Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

SNS-062-Drug Profile 129

Product Description 129

Mechanism Of Action 129

R&D Progress 129

TAB-08-Drug Profile 131

Product Description 131

Mechanism Of Action 131

R&D Progress 131

tocilizumab-Drug Profile 133

Product Description 133

Mechanism Of Action 133

R&D Progress 133

B-Cell Chronic Lymphocytic Leukemia-Dormant Projects 141

B-Cell Chronic Lymphocytic Leukemia-Discontinued Products 144

B-Cell Chronic Lymphocytic Leukemia-Product Development Milestones 145

Featured News & Press Releases 145

Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement 145

Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 145

Appendix 146

Methodology 146

Coverage 146

Secondary Research 146

Primary Research 146

Expert Panel Validation 146

Contact Us 146

Disclaimer 147

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2016 11

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

B-Cell Chronic Lymphocytic Leukemia-Pipeline by AB Science SA, H2 2016 22

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Aduro BioTech, Inc., H2 2016 23

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Amgen Inc., H2 2016 24

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Celgene Corporation, H2 2016 25

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Cell Source, Inc., H2 2016 26

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Dynavax Technologies Corporation, H2 2016 27

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Eisai Co., Ltd., H2 2016 28

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Elsalys Biotech SAS, H2 2016 29

B-Cell Chronic Lymphocytic Leukemia-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 30

B-Cell Chronic Lymphocytic Leukemia-Pipeline by iDD biotech SAS, H2 2016 31

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Immunomedics, Inc., H2 2016 32

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Johnson & Johnson, H2 2016 33

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Juno Therapeutics Inc., H2 2016 34

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016 35

B-Cell Chronic Lymphocytic Leukemia-Pipeline by MedImmune, LLC, H2 2016 36

B-Cell Chronic Lymphocytic Leukemia-Pipeline by MEI Pharma, Inc., H2 2016 37

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 38

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Molecular Templates Inc., H2 2016 39

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Noxxon Pharma AG, H2 2016 40

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 41

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 42

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016 43

B-Cell Chronic Lymphocytic Leukemia-Pipeline by TheraMAB LLC, H2 2016 44

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Unum Therapeutics, Inc., H2 2016 45

Assessment by Monotherapy Products, H2 2016 46

Assessment by Combination Products, H2 2016 47

Number of Products by Stage and Target, H2 2016 49

Number of Products by Stage and Mechanism of Action, H2 2016 51

Number of Products by Stage and Route of Administration, H2 2016 53

Number of Products by Stage and Molecule Type, H2 2016 55

B-Cell Chronic Lymphocytic Leukemia-Dormant Projects, H2 2016 141

B-Cell Chronic Lymphocytic Leukemia-Dormant Projects (Contd..1), H2 2016 142

B-Cell Chronic Lymphocytic Leukemia-Dormant Projects (Contd..2), H2 2016 143

B-Cell Chronic Lymphocytic Leukemia-Discontinued Products, H2 2016 144

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2016 11

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 46

Number of Products by Top 10 Targets, H2 2016 48

Number of Products by Stage and Top 10 Targets, H2 2016 48

Number of Products by Top 10 Mechanism of Actions, H2 2016 50

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 50

Number of Products by Routes of Administration, H2 2016 52

Number of Products by Stage and Routes of Administration, H2 2016 52

Number of Products by Top 10 Molecule Types, H2 2016 54

Number of Products by Stage and Top 10 Molecule Types, H2 2016 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AB Science SA

Aduro BioTech, Inc.

Amgen Inc.

Celgene Corporation

Cell Source, Inc.

Dynavax Technologies Corporation

Eisai Co., Ltd.

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd.

iDD biotech SAS

Immunomedics, Inc.

Johnson & Johnson

Juno Therapeutics Inc.

Lymphocyte Activation Technologies, S.A.

MedImmune, LLC

MEI Pharma, Inc.

Millennium Pharmaceuticals Inc

Molecular Templates Inc.

Noxxon Pharma AG

Ono Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals Inc

Sunesis Pharmaceuticals, Inc.

TheraMAB LLC

Unum Therapeutics, Inc.

B-Cell Chronic Lymphocytic Leukemia Therapeutic Products under Development, Key Players in B-Cell Chronic Lymphocytic Leukemia Therapeutics, B-Cell Chronic Lymphocytic Leukemia Pipeline Overview, B-Cell Chronic Lymphocytic Leukemia Pipeline, B-Cell Chronic Lymphocytic Leukemia Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand